Clinical Trial Update: Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy [Phase 2]

View source ↗

Summary

Phase 2 study of RAP-219 in adults with refractory focal epilepsy has completed, reporting on safety and efficacy outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Onset Seizures

Drugs mentioned

• RAP-219

Snippet

Sponsor: Rapport Therapeutics Inc. | Conditions: Focal Onset Seizures | Phase 2 | Status: COMPLETED